Emalex Receives U.S. Patent for Orally Disintegrating Ecopipam Formulation

The new drug formulation could provide a more convenient treatment option.

Apr. 9, 2026 at 4:37pm

Got story updates? Submit your updates here. ›

An extreme close-up X-ray photograph showing the internal structure of an open human mouth with a translucent, glowing tablet dissolving on the tongue, conceptually representing an innovative oral drug formulation.A new orally disintegrating drug formulation aims to make a neurological treatment more accessible and convenient for patients.Chicago Today

Emalex, a pharmaceutical company, has received a U.S. patent for an orally disintegrating formulation of their drug ecopipam. This new formulation is designed to dissolve quickly in the mouth, potentially making it easier for patients to take the medication.

Why it matters

Ecopipam is used to treat certain neurological and psychiatric disorders. An orally disintegrating formulation could improve patient compliance and access to the drug, as it may be easier for some patients to take compared to traditional tablet or capsule forms.

The details

The patented formulation uses proprietary technology to create an orally disintegrating tablet that dissolves rapidly in the mouth. This could provide a more convenient treatment option for patients who have difficulty swallowing traditional solid oral dosage forms.

  • Emalex received the U.S. patent for the orally disintegrating ecopipam formulation on April 9, 2026.

The players

Emalex

A pharmaceutical company that develops treatments for neurological and psychiatric disorders.

Ecopipam

A drug developed by Emalex to treat certain neurological and psychiatric conditions.

Got photos? Submit your photos here. ›

What’s next

Emalex plans to further develop the orally disintegrating ecopipam formulation and seek regulatory approval for its use.

The takeaway

This new orally disintegrating formulation of ecopipam could improve patient access and compliance for those seeking treatment for neurological or psychiatric disorders, providing a more convenient dosage option.